LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 185

Search options

  1. Article ; Online: Screening for Cardiovascular Disease in CKD: CON.

    Ramos, Giana K / Charytan, David M

    Kidney360

    2022  Volume 3, Issue 11, Page(s) 1836–1838

    MeSH term(s) Humans ; Cardiovascular Diseases/complications ; Nephrology ; Renal Insufficiency, Chronic/complications
    Language English
    Publishing date 2022-02-28
    Publishing country United States
    Document type Journal Article
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0004742021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Cardiovascular Risk Prediction Scores in CKD: What Are We Missing?

    Soomro, Qandeel H / Charytan, David M

    Journal of the American Society of Nephrology : JASN

    2022  Volume 33, Issue 3, Page(s) 462–464

    MeSH term(s) Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Female ; Heart Disease Risk Factors ; Humans ; Male ; Renal Insufficiency, Chronic/complications ; Risk Assessment ; Risk Factors
    Language English
    Publishing date 2022-02-10
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1085942-1
    ISSN 1533-3450 ; 1046-6673
    ISSN (online) 1533-3450
    ISSN 1046-6673
    DOI 10.1681/ASN.2022010039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation.

    Mavrakanas, Thomas A / Charytan, David M

    Kidney360

    2022  Volume 3, Issue 10, Page(s) 1769–1771

    Abstract: In patients with atrial fibrillation on dialysis, the incidence of stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription.In patients with atrial fibrillation on dialysis who were on a P2Y12 inhibitor, apixaban increased ...

    Abstract In patients with atrial fibrillation on dialysis, the incidence of stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription.In patients with atrial fibrillation on dialysis who were on a P2Y12 inhibitor, apixaban increased the risk of bleeding, compared with no anticoagulation.The incidence of myocardial infarction or ischemic stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription status.
    MeSH term(s) Humans ; Atrial Fibrillation/complications ; Renal Dialysis/adverse effects ; Pyridones/adverse effects ; Prescriptions
    Chemical Substances apixaban (3Z9Y7UWC1J) ; Pyridones
    Language English
    Publishing date 2022-08-01
    Publishing country United States
    Document type Journal Article
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0003002022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: To Cool the Dialysate or Not? Question Answered?

    Mc Causland, Finnian R / Charytan, David M

    Clinical journal of the American Society of Nephrology : CJASN

    2023  

    Language English
    Publishing date 2023-06-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.0000000000000227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Deep Learning Using Electrocardiograms in Patients on Maintenance Dialysis.

    Zheng, Zhong / Soomro, Qandeel H / Charytan, David M

    Advances in kidney disease and health

    2023  Volume 30, Issue 1, Page(s) 61–68

    Abstract: Cardiovascular morbidity and mortality occur with an extraordinarily high incidence in the hemodialysis-dependent end-stage kidney disease population. There is a clear need to improve identification of those individuals at the highest risk of ... ...

    Abstract Cardiovascular morbidity and mortality occur with an extraordinarily high incidence in the hemodialysis-dependent end-stage kidney disease population. There is a clear need to improve identification of those individuals at the highest risk of cardiovascular complications in order to better target them for preventative therapies. Twelve-lead electrocardiograms are ubiquitous and use inexpensive technology that can be administered with minimal inconvenience to patients and at a minimal burden to care providers. The embedded waveforms encode significant information on the cardiovascular structure and function that might be unlocked and used to identify at-risk individuals with the use of artificial intelligence techniques like deep learning. In this review, we discuss the experience with deep learning-based analysis of electrocardiograms to identify cardiovascular abnormalities or risk and the potential to extend this to the setting of dialysis-dependent end-stage kidney disease.
    MeSH term(s) Humans ; Renal Dialysis/adverse effects ; Artificial Intelligence ; Deep Learning ; Kidney Failure, Chronic/diagnosis ; Electrocardiography
    Language English
    Publishing date 2023-02-01
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2949-8139
    ISSN (online) 2949-8139
    DOI 10.1053/j.akdh.2022.11.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Introduction: Cardiovascular Disease in Chronic Kidney Disease.

    Charytan, David M

    Seminars in nephrology

    2018  Volume 38, Issue 6, Page(s) 541

    MeSH term(s) Cardiovascular Diseases/complications ; Humans ; Renal Insufficiency, Chronic/complications
    Language English
    Publishing date 2018-11-07
    Publishing country United States
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 604652-6
    ISSN 1558-4488 ; 0270-9295
    ISSN (online) 1558-4488
    ISSN 0270-9295
    DOI 10.1016/j.semnephrol.2018.08.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure.

    Soomro, Qandeel H / Charytan, David M

    Clinical journal of the American Society of Nephrology : CJASN

    2021  Volume 16, Issue 6, Page(s) 843–845

    MeSH term(s) Glomerular Filtration Rate ; Humans ; Mineralocorticoid Receptor Antagonists/adverse effects ; Renal Insufficiency ; Stroke Volume
    Chemical Substances Mineralocorticoid Receptor Antagonists
    Language English
    Publishing date 2021-05-27
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.04460421
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces.

    Soomro, Qandeel H / Charytan, David M

    Current opinion in nephrology and hypertension

    2021  Volume 30, Issue 2, Page(s) 198–207

    Abstract: Purpose of review: Several nontraditional risk factors have been the focus of research in an attempt to understand the disproportionately high cardiovascular morbidity and mortality in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) ... ...

    Abstract Purpose of review: Several nontraditional risk factors have been the focus of research in an attempt to understand the disproportionately high cardiovascular morbidity and mortality in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) populations. One such category of risk factors is cardiovascular autonomic dysfunction. Its true prevalence in the CKD/ESKD population is unknown but existing evidence suggests it is common. Due to lack of standardized diagnostic and treatment options, this condition remains undiagnosed and untreated in many patients. In this review, we discuss current evidence pointing toward the role of autonomic nervous system (ANS) dysfunction in CKD, building off of crucial historical evidence and thereby highlighting the areas in need for future research interest.
    Recent findings: There are several key mediators and pathways leading to cardiovascular autonomic dysfunction in CKD and ESKD. We review studies exploring the mechanisms involved and discuss the current measurement tools and indices to evaluate the ANS and their pitfalls. There is a strong line of evidence establishing the temporal sequence of worsening autonomic function and kidney function and vice versa. Evidence linking ANS dysfunction and arrhythmia, sudden cardiac death, intradialytic hypotension, heart failure and hypertension are discussed.
    Summary: There is a need for early recognition and referral of CKD and ESKD patients suspected of cardiovascular ANS dysfunction to prevent the downstream effects described in this review.There are many unknowns in this area and a clear need for further research.
    MeSH term(s) Autonomic Nervous System ; Cardiovascular Diseases/epidemiology ; Cardiovascular System ; Disease Progression ; Humans ; Kidney Failure, Chronic/diagnosis ; Kidney Failure, Chronic/epidemiology ; Kidney Failure, Chronic/therapy ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/therapy
    Language English
    Publishing date 2021-01-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1151092-4
    ISSN 1473-6543 ; 1535-3842 ; 1062-4813 ; 1062-4821
    ISSN (online) 1473-6543 ; 1535-3842
    ISSN 1062-4813 ; 1062-4821
    DOI 10.1097/MNH.0000000000000686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Hydralazine-Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis.

    Mavrakanas, Thomas A / Soomro, Qandeel H / Charytan, David M

    Kidney international reports

    2022  Volume 7, Issue 6, Page(s) 1332–1340

    Abstract: Introduction: The combination of hydralazine-isosorbide dinitrate (H-ISDN) has potential as a heart failure (HF) therapy in the setting of maintenance dialysis.: Methods: In this retrospective study, we analyzed the efficacy of H-ISDN using United ... ...

    Abstract Introduction: The combination of hydralazine-isosorbide dinitrate (H-ISDN) has potential as a heart failure (HF) therapy in the setting of maintenance dialysis.
    Methods: In this retrospective study, we analyzed the efficacy of H-ISDN using United States Renal Data System (USRDS) data. We identified all adult patients with a history of HF on maintenance dialysis between January 1, 2011, and December 31, 2016, with at least 1 prescription for H-ISDN. Baseline characteristics, prescriptions, and outcomes were retrieved from institutional and physician claims. The primary outcome was death from any cause. Additional outcomes included cardiovascular death, sudden cardiac death, hospitalization for HF, an inpatient diagnosis of myocardial infarction (MI), or new-onset atrial fibrillation. Stabilized inverse probability weights were estimated using relevant baseline characteristics and were used in Cox proportional hazards regression.
    Results: We identified 6306 patients who were treated with H-ISDN and 75,509 patients who did not receive H-ISDN. The crude all-cause mortality rate was lower in patients treated with H-ISDN (16.0 events/100 patient years [PYs]) than in nonusers (27.9/100-PY). H-ISDN use was independently associated with lower mortality: hazard ratio (HR) 0.48 (95% CI 0.43-0.54). Cardiovascular death and sudden cardiac death were less common among H-ISDN users than nonusers, Weighted HR was 0.62 (95% CI 0.53-0.71) and 0.62 (95% CI 0.52-0.73), respectively. In contrast, HF admission and MI were more frequent in patients treated with H-ISDN (195.5 and 18.0 events/100-PY) compared with nonusers (73.4 and 10.2 events/100-PY).
    Conclusion: H-ISDN therapy may improve cardiovascular outcomes in maintenance dialysis patients with HF.
    Language English
    Publishing date 2022-04-06
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2022.03.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Spironolactone in Dialysis: What's Old Is New Again.

    Charytan, David M

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2016  Volume 68, Issue 4, Page(s) 512–514

    Language English
    Publishing date 2016
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2016.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top